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AMP-activated protein kinase (AMPK) is a master
sensor and regulator of cellular energy status. Upon
metabolic stress, AMPK suppresses anabolic and
promotes catabolic processes to regain energy ho-
meostasis. Cancer cells can occasionally suppress
the growth-restrictive AMPK pathway by mutation
of an upstream regulatory kinase. Here, we describe
awidespreadmechanism to suppress AMPK through
its ubiquitination and degradation by the cancer-spe-
cific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3
andMAGE-A6 are highly similar proteins normally ex-
pressed only in the male germline but frequently
re-activated in human cancers. MAGE-A3/6 are
necessary for cancer cell viability and are sufficient
to drive tumorigenic properties of non-cancerous
cells. Screening for targets of MAGE-A3/6-TRIM28
revealed that it ubiquitinates and degrades AMPKa1.
This leads to inhibition of autophagy, activation of
mTOR signaling, and hypersensitization to AMPK ag-
onists, such as metformin. These findings elucidate a
germline mechanism commonly hijacked in cancer to
suppress AMPK.
INTRODUCTION
Cells must coordinate multiple metabolic processes in order to
balance their energy usage with nutrient availability. One promi-
nent way that this balance is accomplished is through the activity
of the AMP-activated protein kinase (AMPK). AMPK is a hetero-
trimeric kinase comprised of catalytic a and regulatory b and g
subunits that is regulated by the cellular concentrations of
ATP, ADP, and AMP (Hardie et al., 2012b). When cellular levels
of ATP fall and ADP/AMP rise, ATP that is bound to the g subunit
is replaced by ADP and/or AMP, resulting in activation of the cat-
alytic kinase subunit (Landgraf et al., 2013; Suter et al., 2006).
Once activated, AMPK generally opposes anabolic energy-
consuming pathways while promoting catabolic ATP-generating
pathways. For example, AMPK inhibits ACC1 and mTOR to
block fatty acid and protein synthesis, respectively, while atthe same time it promotes autophagy via multiple pathways
involving mTOR, ULK1, and VPS34 (Egan et al., 2011; Gwinn
et al., 2008; Hardie et al., 2012b; Kim et al., 2011, 2013). In addi-
tion to changes in energy levels, upstream kinases such as
LKB1/STK11 and CaMKK regulate AMPK activity by phosphor-
ylation of its activation loop at T172 (Hawley et al., 2003, 2005;
Shaw et al., 2004; Woods et al., 2005).
Although AMPKmay in some cases promote late-stage tumor
growth (Laderoute et al., 2014), multiple lines of evidence sug-
gest AMPK has critical tumor suppressor activities in both
humans and experimental models, including mice (Hardie and
Alessi, 2013; Shackelford and Shaw, 2009). For example,
knockout of AMPKa1 in the mouse accelerates development
of c-Myc-driven lymphomas (Faubert et al., 2013). AMPK’s role
in suppressing tumor initiation and progression is multifaceted,
including growth suppression by inhibiting synthesis of cellular
macromolecules (Hardie et al., 2012b), particularly through
downregulating the mTOR signaling pathway (Gwinn et al.,
2008; Inoki et al., 2003), and promoting cell-cycle arrest through
stabilizing p53 and cyclin-dependent kinase inhibitors (Imamura
et al., 2001; Jones et al., 2005; Liang et al., 2007). Additionally,
AMPK can oppose theWarburg effect in favor of oxidative phos-
phorylation through upregulating oxidative enzymes and pro-
moting mitochondrial biogenesis (Canto´ et al., 2009; Winder
et al., 2000). Furthermore, AMPK has recently been shown to
inhibit epithelial-to-messenchymal transition (EMT) by modu-
lating the Akt-MDM2-Foxo3 signaling axis (Chou et al., 2014).
Given the importance of metabolic control and AMPK’s role as
master sensor and regulator of cellular energy, it is not surprising
that this signaling axis is de-regulated in a variety of disease
states, including cancer (Hardie and Alessi, 2013; Shackelford
et al., 2009). For example, in approximately 20% of lung adeno-
carcinomas and cervical cancers, signaling through this axis is
reduced by loss-of-function mutation or deletion of Lkb1/Stk11
(Matsumoto et al., 2007; Sanchez-Cespedes et al., 2002; Wingo
et al., 2009). Additionally, AMPK levels have been shown to be
reduced in some cases of hepatocellular carcinomas and B-
RAF V600E can downregulate AMPK signaling through inhibition
of Lkb1/Stk11 in melanomas (Esteve-Puig et al., 2009; Lee et al.,
2012; Zheng et al., 2009; Zheng et al., 2013). From thesemultiple
lines of converging evidence on AMPK’s critical role in tumor
suppression, there is great interest in the utilization of com-
pounds that stimulate AMPK activity, such as metformin, in theCell 160, 715–728, February 12, 2015 ª2015 Elsevier Inc. 715
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prevention and treatment of cancer and many clinical trials are
ongoing (Hadad et al., 2011; Hardie et al., 2012a; Niraula et al.,
2012; Pernicova and Korbonits, 2014).
Melanoma antigen (MAGE) genes are conserved in all eukary-
otes, encode for proteins with a common MAGE homology
domain, and have rapidly expanded to comprise almost 50
unique genes in humans (Chomez et al., 2001; Feng et al.,
2011). Approximately two-thirds of human MAGEs are consid-
ered cancer-testis antigens because they are normally restricted
to expression in the testis but are aberrantly re-expressed in can-
cer and have antigenic properties (Simpson et al., 2005). The
functional significance of MAGEs in tumors is not well under-
stood, but accumulating evidence supports their importance.
For example, knockdown of MAGE-A3/6 impairs tumor growth
in mice, whereas expression of MAGE-A3 in MAGE-negative
cells drives tumor growth and metastasis in vivo (Liu et al.,
2008; Yang et al., 2007). Importantly, we recently showed that
a defining characteristic of MAGE proteins is their ability to
bind and potentiate the activity of specific E3 ubiquitin ligases
(Doyle et al., 2010). For example, MAGE-L2 binds to the
TRIM27 ubiquitin ligase and promotes ubiquitination of the
WASH actin assembly complex to facilitate endosomal protein
recycling (Hao et al., 2013).
Here, we present evidence for a regulatory axis engaged in
cancer cells that downregulates AMPK through ubiquitination
and degradation of AMPKa1 by the normally testis-restricted
MAGE-A3/6-TRIM28 E3 ubiquitin ligase complex activated in
cancer. These findings identify a widespread mechanism for
downregulating AMPK signaling during tumorigenesis and eluci-
date an unanticipatedmechanism of action for oncogenic MAGE
cancer-testis antigens.
RESULTS
MAGE-A3 and MAGE-A6 Are Physiologically Restricted
to Expression in the Testis but Are Aberrantly Expressed
in Cancer
MAGE-A3 and MAGE-A6 are highly similar, neighboring genes
located on the X chromosome that encode proteins with 96%
identity (Figures S1A and S1B). Given their homology and func-
tional redundancy (see below), we refer to these genes as simply
MAGE-A3/6 herein. To thoroughly examine the expression
pattern of MAGE-A3/6, we analyzed their expression by quanti-
tative RT-PCR (qRT-PCR) in >50 mouse tissues from two strains
of mice (C57BL/6 and BALB/C). Consistent with previous find-
ings (De Plaen et al., 1994), mouse MAGE-A3/6 were completely
restricted to expression in the testis with no detectable expres-
sion in any other tissue (Figures 1A, 1B, S1C, and S1D). We
extended these analyses to a panel of >20 human tissues andFigure 1. MAGE-A3 and MAGE-A6 Are Normally Restricted to Express
Poor Patient Prognosis
(A and B) qRT-PCR analysis (n = 3) of the normalized expression of mouse MAG
(C) qRT-PCR analysis (n = 3) of the normalized expression of human MAGE-A3/6
(D and E) Percentage of patient tumors expressing MAGE-A3 (D) and MAGE-A6
(F–H) MAGE-A3 and MAGE-A6 are co-expressed in breast invasive carcinomas
(I and J) Expression of MAGE-A3 (C) or MAGE-A6 (D) in patients with lung squam
Data are represented as the mean ± SD. Asterisks indicate p < 0.05. See also Fifound that human MAGE-A3/6 are similarly restricted to expres-
sion only in the human testis (Figure 1C). Like other cancer-testis
antigen genes, MAGE-A3/6 have been reported to be aberrantly
expressed in tumors (Jang et al., 2001; Shantha Kumara et al.,
2012). Our analysis of a variety of different tumor types from
patients revealed that MAGE-A3/6 are commonly expressed
in many cancer types, including breast invasive carcinomas
(25%), colon adenocarcinomas (50%), and lung squamous cell
carcinomas (75%; Figures 1D and 1E). Additionally, expression
of MAGE-A3 andMAGE-A6was significantly correlated in breast
invasive carcinomas, colon adenocarcinomas, and lung squa-
mous cell carcinomas (Figures 1F–1H). However, expression of
MAGE-A3 was not significantly correlated with expression of un-
related MAGE-A11 or MAGE-B2 (Figures S1E and S1F), sug-
gesting that MAGE-A3 and MAGE-A6 expression is selectively
coordinated. Furthermore, to determine whether MAGE-A3/6
expression correlates with patient outcome, we analyzed
whether expression of MAGE-A3/6 correlates with overall sur-
vival. Indeed, patients with lung squamous cell carcinomas ex-
pressing MAGE-A3 or MAGE-A6 have a significant decrease in
overall survival time (Figures 1I and 1J). Patients with tumors ex-
pressing MAGE-A3 had a >50% reduced overall survival time
compared to patients withMAGE-A3-negative tumors (30 versus
69 months, respectively; 2.0 hazard ratio; Table S1). Similarly,
patients with tumors expressing MAGE-A6 had a >50% reduced
survival time (33 versus 71months; hazard ratio of 1.9; Table S1).
Together, these results suggest MAGE-A3/6 are physiologically
restricted to the testis in both humans and mice but are
frequently found in a wide variety of cancer types, and their
expression correlates with poor patient prognosis.
MAGE-A3/6 Are Required for Cancer Cell Viability and
Function as Oncogenes
MAGE-A3/6 could be ‘‘passenger’’ genes that have little func-
tional role or significance in tumorigenesis and are simply bio-
markers. Alternatively, MAGE-A3/6 may be oncogenic ‘‘driver’’
genes that are involved in promoting tumor initiation and/or pro-
gression. To determine if MAGE-A3/6 have important functional
roles in cancer cells, we examined whether patient-derived
breast, colon, and lung cancer cells require the expression of
MAGE-A3/6 for viability. Indeed, knockdown of MAGE-A3/6 us-
ing two independent small interfering RNAs (siRNAs) (Figures
S2A and S2B) in multiple lung (HCC193, H1648, and H2126),
breast (HCC1806 and SK-BR-3), and colon (HCT116 and
HT29) cancer cells resulted in a significant decrease in cell
viability and clonogenic survival (Figures 2A–2C, S2C, and
S2D). Importantly, these effects are likely on target, because
MAGE-A3/6 siRNAs do not significantly alter the viability of
MAGE-A3/6-negative cells (HCC1143 and DLD1), even thoughion in the Testis but Are Aberrantly Expressed in Cancer and Predict
E-A3 (A) and MAGE-A6 (B) in the indicated tissues from BALB/C mice.
(one primer set detects both) in the indicated human tissues.
(E) is shown.
(F), colorectal adenocarcinomas (G), and lung squamous cell carcinomas (H).
ous carcinomas correlates with poor overall survival.
gure S1 and Table S1.
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Figure 2. MAGE-A3/6 Are Potent Onco-
genes Whose Expression Is Necessary for
Viability of Cancer Cells and Is Sufficient to
Transform Cells
(A–C) MAGE-A3/6 depletion reduces viability of
MAGE-A3/6-expressing tumor cell lines. Lung (A),
breast (B), and colon (C) cancer cells were treated
with siControl, two distinct siMAGE-A3/6, or
cytotoxic siUbiquitinB for a transfection control.
Cell viability was measured by MTT assay.
(D) MAGE-A3 and MAGE-A6 have oncogenic ac-
tivity. NIH 3T3 fibroblasts were transfected with
MAGE-A3, MAGE-A6, or mutant K-Rasv12 as a
positive control, and foci formation was assayed.
Foci were stained with crystal violet and counted.
(E) MAGE-A6 promotes anchorage-independent
growth of DLD1 colon cancer cells. MAGE-A-
negative DLD1 cells stably expressing vector or
MAGE-A6 were assayed for anchorage-indepen-
dent growth in soft agar colony formation assays.
(F and G) MAGE-A6 promotes anchorage-inde-
pendent growth of non-transformed, immortalized
human colonic epithelial cells (HCECs) without (F)
or with (G) expression of mutant K-Rasv12. The
indicated HCEC cells were assayed for anchorage-
independent growth in soft agar colony formation
assays.
Data (n = 3) are represented as the mean ± SD.
Asterisks indicate p < 0.05. See also Figure S2.the cytotoxic siRNA targeting ubiquitin B was just as lethal in all
cell lines (Figures 2A–2C). These results suggest that upon
expression of MAGE-A3/6, cells become dependent on their
expression for viability, similar to other reports of ‘‘oncogene
addiction’’ (Weinstein, 2002).
To determine whether MAGE-A3/6 are indeed oncogenic
driver genes, we analyzed their activity in several classical as-
says. First, expression of either MAGE-A3 or MAGE-A6 signifi-
cantly stimulated foci formation of NIH 3T3 cells (Figure 2D).
Furthermore, MAGE-A6 promoted other hallmarks of cancer,
such as anchorage-independent growth of the MAGE-A3/6-
negative DLD1 colon cancer cells (Figure 2E). Finally, to more
stringently assay the oncogenic activity of MAGE-A3/6, we
determined the ability of MAGE-A6 to promote tumorigenic phe-
notypes in non-transformed, human colonic epithelial cells
(HCECs) derived from normal colon biopsies and immortalized
with CDK4 and hTERT (Roig et al., 2010). Remarkably, stable
expression ofMAGE-A6 alonewas sufficient to drive transforma-
tion of these cells, resulting in robust anchorage-independent
growth in soft agar (Figure 2F). In this setting, the oncogenic ac-
tivity of MAGE-A6 was even more robust than expression of the
bona fide K-Rasv12 oncogene (Figure 2F). Additionally, even in718 Cell 160, 715–728, February 12, 2015 ª2015 Elsevier Inc.the context of mutant K-Rasv12 expres-
sion, MAGE-A6 was still competent to
drive anchorage-independent growth of
HCEC cells to a similar degree as the
Apcmin oncogene (Figure 2G). Consistent
with these findings, MAGE-A3/6 drives
increased tumor growth and metastasis
in an orthotopic xenograft mouse modelof thyroid cancer (Liu et al., 2008). Collectively, these findings
suggest that MAGE-A3/6 are potent driver oncogenes that
have therapeutic potential.
The MAGE-A3/6-TRIM28 E3 Ubiquitin Ligase
Ubiquitinates and Degrades AMPKa1
Previously, we reported that MAGE proteins, including MAGE-
A3/6, form complexes with specific E3 ubiquitin ligases to regu-
late ubiquitination (Doyle et al., 2010; Hao et al., 2013). MAGE-
A3/6 specifically bind to the TRIM28 E3 ubiquitin ligase, also
known as KAP1 (Doyle et al., 2010). We and others have previ-
ously shown that MAGE-A proteins can inhibit the critical p53
tumor suppressor, including via MAGE-A-TRIM28-induced
ubiquitination and proteasome-mediated degradation of p53
(Doyle et al., 2010; Marcar et al., 2010; Monte et al., 2006;
Wang et al., 2005; Yang et al., 2007). However, several of the
cell lines dependent on MAGE-A3/6 for viability (Figures 2A–
2C) are p53 null (HCC1806 and H1648) or mutant (HCC193,
SK-BR-3, and HT-29). Additionally, MAGE-A3/6 stimulated
anchorage-independent growth in p53 mutant DLD1 colon can-
cer cells (Figure 2E). Furthermore, expression of MAGE-A3/6 did
not inversely correlate with p53 mutational status (c2 = 0.17;
p = 0.98). Therefore, the MAGE-A3/6-TRIM28 E3 ubiquitin ligase
may have additional targets relevant to its function in cancer
cells.
To identify additional targets of the MAGE-TRIM28 E3 ubiqui-
tin ligase, we screened for its direct substrates by performing
in vitro ubiquitination reactions on protein microarrays contain-
ing >9,000 SF9-purified, recombinant proteins (Figure 3A). This
screen yielded 19 potential MAGE-TRIM28 substrates (Table
S2) whose ubiquitination were significantly (p < 0.05) increased
by MAGE-TRIM28. To validate the results of the screen, candi-
dates were tested for regulation by MAGE-A3/6-TRIM28, with
AMPKa1 being the most consistent and robust target of
MAGE-A3/6-TRIM28 (Figures 3B–3D). Multiple siRNAs targeting
MAGE-A3/6 or TRIM28 decreased ubiquitination of AMPKa1
(Figures 3B and S2F). Expression of MAGE-A3 in MAGE-A3/6-
negative cells promoted ubiquitination of AMPKa1 (Figure 3C).
Furthermore, knockdown of MAGE-A3/6 or TRIM28 resulted in
increased AMPKa1 protein levels (Figure 3D), without affecting
mRNA levels (Figure 3E). Additional subunits of the AMPK holo-
enzyme complex, such as AMPKb1 and AMPKg1, were corre-
spondingly elevated (Figure S2G). In contrast, expression of
MAGE-A3 in MAGE-A3/6-negative cells decreased AMPKa1
protein levels (Figure 3F), without affecting mRNA levels (Fig-
ure S2E). Notably, AMPKa1 protein levels could be rescued by
addition of theMG132 proteasome inhibitor (Figure 3F), suggest-
ing that MAGE-A3/6-TRIM28 ubiquitination of AMPKa1 leads to
its degradation by the proteasome.
To determine if MAGE-A3/6 enhances degradation of AMPKa1
by TRIM28, as is the case for p53 (Doyle et al., 2010), or if MAGE-
A3/6 is required for specifying AMPKa1 degradation by TRIM28,
we examined whether TRIM28 regulates AMPKa1 levels in
MAGE-A3/6-negative cells. Knockdown of TRIM28 in MAGE-
A3/6-negative cells had no effect on AMPKa1 levels (Figure 3G),
suggesting thatMAGE-A3/6 is required for AMPKa1 degradation
by TRIM28. Consistent with this notion, the AMPKa1b1g1 holo-
enzyme complex (Figure S2H) and specifically AMPKa1 bound
to recombinant GST-MAGE-A3 and GST-MAGE-A6, but not
GST-TRIM28 in vitro (Figure 3H). Additionally, overexpressed
and endogenous AMPKa1 co-immunoprecipated with MAGE-
A3 from cells (Figures 3I and S2I). These results suggest that
MAGE-A3/6 specifies ubiquitination of AMPKa1 by the TRIM28
ubiquitin ligase.
Inhibition of AMPK by MAGE-A3/6-TRIM28 Impacts
Cellular Metabolic Processes
Next, we determined whether modulation of AMPK protein levels
by MAGE-A3/6-TRIM28 had a functional impact on AMPK activ-
ity and the cellular metabolic processes it controls. Knockdown
of MAGE-A3/6 or TRIM28 increased both total and active (phos-
phorylated, pT172) AMPKa1 (Figure 4A). Furthermore, the
knockdown of MAGE-A3/6 or TRIM28 resulted in increased
phosphorylation of ACC1 (Figure 4B), a prototypical target of
AMPK (Carling et al., 1987). Although AMPK generally antago-
nizes the Warburg effect (Faubert et al., 2013), acute stimulation
of AMPK can promote glycolysis through a variety of activities,
including plasma membrane localization of the GLUT1 glucose
transporter and increased glucose consumption (Barnes et al.,
2002; Hardie et al., 2012b). Knockdown of MAGE-A3/6 orTRIM28 resulted in increased plasma membrane localized
GLUT1 (Figure 4C). Furthermore, knockdown of TRIM28 in-
creased glucose consumption (Figure 4D) and correspondingly
increased lactate production (Figure 4E) in MAGE-A3/6-positive
cells. These results suggest that MAGE-A3/6-TRIM28 has a
functional impact on cellular metabolism.
In addition to regulating cellular glucose metabolism, AMPK is
well documented to inhibit anabolic processes, such as mTOR-
dependent protein synthesis, to conserve energy in the context
of reduced ATP levels (Gwinn et al., 2008; Inoki et al., 2003).
Therefore, we knocked down MAGE-A3/6 or TRIM28 and fol-
lowed mTOR activity by examining phosphorylation of p70 ribo-
somal S6 kinase and ribosomal S6 protein. Upon knockdown of
MAGE-A3/6 or TRIM28, mTOR signaling was severely inhibited
and phosphorylation of both p70 ribosomal S6 kinase and ribo-
somal S6 protein were reduced (Figure 4F). Similarly, amino-
acid-induced mTOR activity was significantly reduced upon
depletion of MAGE-A3/6 (Figure 4G). Importantly, reduction in
basal mTOR activity was rescued by treatment with the AMPK
inhibitor, compound c (Figure 4H), or co-depletion of AMPKa1
(Figure 4I). Together, these results suggest that the MAGE-A3/
6-TRIM28 ubiquitin ligase is functionally important for mainte-
nance of mTOR activity, likely through inhibition of AMPK.
MAGE-A3/6-TRIM28 Ubiquitin Ligase Inhibits
Autophagy
Because MAGE-A3/6-TRIM28 regulates both AMPK and mTOR
activities and both of these signaling pathways converge to op-
posingly modulate autophagy (Egan et al., 2011; Kim et al.,
2011), we examined whether MAGE-A3/6-TRIM28 influences
autophagy. Onemechanism by which AMPK andmTOR regulate
autophagy is through phosphorylation of the proximal ULK1 ki-
nase required for autophagosome formation. AMPK phosphory-
lation of ULK1 S555 promotes ULK1 activity and autophagy,
whereas mTOR phosphorylation of ULK1 S757 inhibits ULK1
activity and autophagy (Egan et al., 2011; Kim et al., 2011).
Knockdown of MAGE-A3/6 or TRIM28 upregulated ULK1 S555
phosphorylation (AMPK site) and downregulated ULK1 S757
phosphorylation (mTOR site) (Figure 5A). Changes in ULK1 phos-
phorylation by MAGE-A3/6 or TRIM28 knockdown were accom-
panied by the expected increase in GFP-LC3 puncta, amarker of
autophagy (Figures 5B and S3A–S3C). The increased GFP-LC3
puncta in MAGE-A3/6- and TRIM28-depleted cells was blocked
by co-depletion of ULK1 (Figure 5C). Themagnitude of increased
GFP-LC3 puncta upon MAGE-A3/6 or TRIM28 knockdown was
similar to knockdown of mTOR, an established potent inhibitor
of autophagy (Figure 5B). To complement our results using cells
stably expressing GFP-LC3, we examined the number of endog-
enous LC3 puncta upon knockdown of MAGE-A3/6. Similarly to
GFP-LC3, siRNAs targeting MAGE-A3/6 induced the accumula-
tion of endogenous LC3 puncta in MAGE-A3/6-positive cells but
had no effect in MAGE-A3/6-negative cells (Figures 5D and 5E).
Importantly, short-term inhibition of AMPK with compound c
attenuated MAGE-A3/6-RNAi-induced GFP-LC3 puncta forma-
tion (Figure 5F).
Since an increase in LC3 puncta may represent either a block
in autophagosome fusion with lysosomes or an increase in auto-
phagy, we measured the consumption (levels) of GFP-LC3 byCell 160, 715–728, February 12, 2015 ª2015 Elsevier Inc. 719
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flow cytometry. We observed a significant decrease in GFP-LC3
fluorescence upon knockdown of MAGE-A3/6 or TRIM28, and
this was again similar to the degree of GFP-LC3 consumption
upon mTOR depletion (Figures 5G and S3D). These results
were further confirmed by western blotting where knockdown
of MAGE-A3/6 or TRIM28 promoted a marked decrease in
GFP-LC3 protein levels (Figure 5H). These changes in GFP-
LC3 were not due to alterations in GFP-LC3 mRNA levels (Fig-
ure S3E). To determine if the decrease in LC3 was the conse-
quence of increased autophagic flux, we treated cells depleted
of MAGE-A3/6 or TRIM28 with bafilomycin A1 to prevent acidifi-
cation of lysosomes and degradation of proteins by autophagy.
Short-term treatment of cells with bafilomycin A1 blocked
consumption of GFP-LC3 by knockdown of MAGE-A3/6 or
TRIM28 (Figure 5I). Finally, we examined the levels of autophagy
in MAGE-A3/6- or TRIM28-depleted cells by an independent
measure, consumption of the p62/SQSTM1 autophagy adaptor.
Similarly to LC3, endogenous p62/SQSTM1 was consumed
upon knockdown of MAGE-A3/6 or TRIM28 (Figure 5J), and
this could be rescued by bafilomycin A1 (Figure 5K). Further-
more, the ability of MAGE-A3/6 to inhibit autophagy was also
confirmed by expression of MAGE-A3 in normal, non-trans-
formed cells that typically are negative for MAGE-A3/6. MAGE-
A3 expression induced the degradation of AMPKa1 and the
accumulation of p62/SQSTM1 (Figure 5L), consistent with
reduced autophagy in these cells. Collectively, these results
suggest that MAGE-A3/6-TRIM28 inhibits autophagy and that
depletion of MAGE-A3/6 or TRIM28 dramatically increases auto-
phagic flux.
MAGE-A3/6 Regulation of AMPKa1 Is Relevant
in Human Tumors
Our results suggest that the oncogenic MAGE-A3/6-TRIM28
ubiquitin ligase regulates several cellular metabolic regulatory
pathways through ubiquitination and degradation of AMPKa1.
To determine the relevance of these findings to human tumors,
we examined whether MAGE-A3/6 expression inversely corre-
lated with AMPK activity and protein levels in patient tumor
samples. Indeed, breast invasive carcinoma (Figure S4A),
colon adenocarcinoma (Figure 6A), and lung squamous cell
carcinoma (Figure 6B) tumors expressing MAGE-A3/6 had
significantly reduced total and active (phospho-T172) AMPKa
protein levels. This reduction was not a consequence of de-
creased AMPKa1 mRNAs in these tumors (Figures 6A, 6B,
and S4A). Consistent with these findings, the phosphorylated
form of AMPK is downregulated in high proportion of cases
of breast cancer (Hadad et al., 2009). In addition, MAGE-A3/
6 expression in tumors correlated with reduced downstream
AMPK signaling, such as increased markers of mTOR activity
(Figure S4B).(F) MAGE-A3 promotes proteasome-dependent AMPKa1 degradation. MAGE-A3
for 4 hr before immunoblotting (n = 3).
(G) TRIM28-mediated AMPKa1 degradation requires MAGE-A3/6. MAGE-A3/6-ne
cell lysates were immunoblotted (n > 3).
(H) GST pull-down assays reveal AMPKa1 directly binds to MAGE-A3 and MAG
(I) HeLa cells expressing FLAG-MAGE-A3 or FLAG-vector along with Myc-AMPK
WCL, whole-cell lysate. Data are representative of multiple experiments (n = 2).Finally, AMPK agonists are of significant interest in treatment
and prevention of cancer (Hardie et al., 2012a). Thus, we deter-
minedwhether AMPK agonists could reverse the phenotypes of
MAGE-A3/6 driven anchorage-independent growth and cancer
cell viability. The AMPK activating compounds, aminoimidazole
carboxamide ribonucleotide (AICAR) and metformin, sup-
pressed the ability of MAGE-A6 to promote anchorage-inde-
pendent growth of normal HCEC cells and DLD1 colon cancer
cells in a dose-dependent manner (Figures S4D–S4F). Impor-
tantly, these effects were specific to MAGE-A6-expressing
cells as AICAR and metformin minimally affected Apcmin or
MAGE-B10 driven anchorage-independent growth of HCEC
cells (Figures S4D and S4E). Since the cellular effects of both
AICAR and metformin extend beyond just activation of AMPK,
including affecting mitochondrial respiration (Hardie et al.,
2012a), we also examined whether a direct allosteric activator
of AMPK, A769662 (Cool et al., 2006; Landgraf et al., 2013),
or genetic manipulation of AMPKa1 could alter phenotypes
associated with MAGE-A3/6. MAGE-A6-induced, but not Apc-
min- or MAGE-B10-induced anchorage-independent growth of
HCEC and DLD1 cells was significantly impaired by A769662
in a dose-dependent manner (Figures 6C and S4G). Further-
more, co-depletion of AMPKa1 rescued MAGE-A3/6-RNAi-
induced decrease in cell viability (Figure 6D). Taken together,
these results suggest that regulation of AMPK by MAGE-A3/6
is relevant to human tumors and pharmacological agonists of
AMPK may have therapeutic potential in MAGE-A3/6-positive
tumors.
DISCUSSION
AMPK senses and responds to the energy status of cells to regu-
late multiple metabolic processes and limit energy expenditure.
Significant effort has been directed toward understanding the
role and dysregulation of AMPK in cancer. One known mecha-
nism of reducing AMPK activity in cancer is mutation/deletion
of its upstream regulatory kinase Lkb1/Stk11. However, this is
a rare event in most tumor types other than lung adenocarci-
nomas and cervical cancers (Wingo et al., 2009). In this study,
we demonstrate that theMAGE-A3/6-TRIM28 E3 ligase complex
ubiquitinates and degrades AMPKa1. Thus, the prominent acti-
vation of MAGE-A3/6 expression in many cancer types may
represent an alternative mechanism for downregulating the
AMPK signaling pathway (Figure S5). Consistent with this,
expression of MAGE-A3/6 andmutation of Lkb1/Stk11 are rarely
found in the same lung adenocarcinoma tumors (Figure S4C,
p < 0.01).
MAGE-A3/6 are normally exclusively expressed in the testis
but are frequently turned on in many tumor types, including co-
lon, lung, and breast tumors (Figure 1). In combination with/6-negative cells expressing vector ofMAGE-A3were treatedwith 5 mMMG132
gative HEK293 cells were transfected with the indicated siRNA for 72 hr before
E-A6, but not TRIM28 (22-418) or GST (n = 3).
a1 were subjected to anti-Myc IP and immunoblotting.
See also Table S2.
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previous studies, our findings suggest that activation of MAGE-
A3/6 in cancer cells is not a by-product, passenger event during
cellular transformation and tumorigenesis, but rather MAGE-A3/
6 are driver genes that support multiple phenotypes associated
with tumors, includingmetabolic dysregulation. We propose that
one critical oncogenic function of MAGE-A3/6 is downregulation
of AMPK and alteration of cellular metabolism in cancer cells.
Strikingly, this mode of AMPK regulation does not occur in
normal somatic cells that do not express MAGE-A3/6 but only
occurs upon reactivation of the testicular MAGE-A3/6 program
in cancer cells.
Although AMPK coordinates many different actions in the
cell, one key process it controls is autophagy. While the role
of autophagy in the progression of cancer is multifaceted,
loss of autophagy has been implicated in the initiation of tumor-
igenesis (Choi et al., 2013; Wei et al., 2013; White, 2012). Our re-
sults suggest that aberrant activation of MAGE-A3/6 in tumors
may provide a unique mechanism for inhibition of tumor-
suppressive autophagy during tumor initiation. Interestingly,
MAGE-A3/6 expression is undetectable in never-smokers but
is aberrantly found in the lungs of smokers before they have
any clinical signs of disease (Jang et al., 2001). Thus, MAGE-
A3/6 expression may occur early during tumor initiation and
could be one mechanism to downregulate autophagy during
this stage. Identification of the factors that regulate MAGE-
A3/6 expression in adult tissues may provide insights into
understanding events leading to tumor initiation. Onemajor reg-
ulatory mechanism controlling expression of MAGE cancer-
testis antigens is promoter CpG methylation in normal somatic
cells (Simpson et al., 2005). However, simple demethylation of
MAGEs is not sufficient to drive expression (Weber et al.,
1994). The identification of additional transcriptional regulators
will be of utmost importance.
Our findings of the association of MAGE-A3/6 expression with
AMPK degradation in human tumors has important and poten-
tially immediate implications on the utilization of AMPK activating
compounds, such as metformin and A769662, that are vigor-
ously being pursued in the prevention and treatment of cancer
(Quinn et al., 2013). While AMPK activating drugs are currently
in clinical trials for treatment of a variety of tumor types, the early
results thus far have been mixed with no apparent explanation
(Quinn et al., 2013). We propose that MAGE-A3/6 expression
status may be a useful enrollment biomarker to select patients
with the greatest potential response to AMPK agonists. Addition-
ally, since MAGE-A3/6 expression increases signaling throughFigure 4. MAGE-A3/6-TRIM28 Ubiquitin Ligase Regulates AMPK-Cont
(A and B) MAGE-A3/6-TRIM28 knockdown increases phospho-AMPK (A) and ph
siRNAs for 72 hr before cell lysates were immunoblotted (n = 3).
(C) MAGE-A3/6-TRIM28 knockdown increases Glut1 plasma membrane locali
immunostaining for Glut1 (n = 3). Scale bar, 20 mm.
(D and E)MAGE-A3/6-TRIM28 knockdown alters glucosemetabolism. HeLa cells
media. After 6 hr, media was collected and glucose (D) and lactate (E) levels in m
(F) MAGE-A3/6-TRIM28 is required for mTOR signaling. HeLa or U2OS cells wer
(G) MAGE-A3/6-TRIM28 is required for amino-acid-induced mTOR activity. HeL
siRNAs for 72 hr before 6 hr starvation in EBSS (0 min) or starvation followed by
(H and I) Inhibition of AMPK reverses mTOR inhibition by MAGE-A3/6 or TRIM28
collection and immunoblotting (I) or treatment for 4 hr with 10 mM compound C o
Asterisks indicate p < 0.05.the mTOR pathway, the use of currently approved mTOR inhib-
itors may be effective in the future treatment of MAGE-A3/6-
driven tumors.
Little is known about the physiological role of MAGE-A3/6 in
the testis. Our findings on the molecular and cellular functions
of MAGE-A3/6-TRIM28 in cancer provide intriguing insights
into their normal physiological function during spermato-
genesis. Interestingly, germ cells in the testis switch their car-
bon energy sources as they differentiate from spermatogonia
stem cells to maturing haploid spermatids (Nakamura et al.,
1984). We propose that MAGE-A3/6 may function to protect
maturing spermatocytes from energy stress by dampening
AMPK activation. Also, MAGE-A3/6 might enable develop-
mental stage-dependent activation of anabolic pathways
required for normal spermatogenesis, such as lipid and protein
synthesis. Furthermore, developing spermatocytes also ex-
press an unusual splice variant of LKB1 with a different C-ter-
minal region, which is required for spermiogenesis (Towler
et al., 2008). Consistent with these ideas, we have found
that mouse MAGE-A genes are highly expressed in pre-pachy-
tene spermatocytes (data not shown) where these regulator
events are occurring and previous studies have shown that
testis-specific knockout of TRIM28 blocks spermatocyte dif-
ferentiation, resulting in testis degeneration (Weber et al.,
2002).
In summary, our findings illuminate a previously unrecognized,
widespread regulation of AMPK during tumorigenesis by a
testis-specific ubiquitin ligase, provide an unprecedented mo-
lecular mechanism by which MAGE cancer-testis antigens drive
tumorigenesis, and have important implications to maximizing
the clinical utility of AMPK-directed chemotherapies.EXPERIMENTAL PROCEDURES
Cell Culture and Transfections
Cells were cultured under standard conditions and transfected according to
manufacturer’s recommendation. Detailed descriptions of cell-culture condi-
tions, transfection procedures, siRNA sequences, and antibodies are
described in Extended Experimental Procedures.RNA Preparation and qRT-PCR
Preparation of RNA from tissues and cells and qRT-PCR analysis was per-
formed by standard molecular biology techniques and described in Extended
Experimental Procedures. All procedures and use of mice were approved by
the Institutional Animal Care and Use Committee of UT Southwestern Medical
Center.rolled Metabolic Processes
ospho-ACC1 (B) signaling. HeLa or U2OS cells were treated with the indicated
zation. HeLa cells were treated with the indicated siRNAs for 72 hr before
were treatedwithMAGE-A3/6 or TRIM28 siRNA for 72 hr and then fedwith fresh
edia were analyzed via nova analyzer. Data (n = 3) represent mean ± SD.
e treated with the indicated siRNAs for 72 hr before immunoblotting (n = 3).
a cells were treated with siControl, siMAGE-A3/6, or siRagC (positive control)
30 min amino acid stimulation (n = 3).
knockdown. Cells were transfected with the indicated siRNAs for 72 hr before
r vehicle (DMSO) (H) (nR 2).
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Figure 5. MAGE-A3/6-TRIM28 Ubiquitin Ligase Inhibits Autophagy
(A) HeLa or U2OS cells were transfected with siRNA for 72 hr before immunoblotting (ULK1 pS555 AMPK target site; ULK1 pS757 mTOR target site)
(n > 3).
(legend continued on next page)
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Figure 6. Regulation of AMPK by MAGE-A3/6-TRIM28 Is Relevant to Human Tumors
(A and B) TCGA data were analyzed for MAGE-A3/6 mRNA levels and total and active (pT172) AMPKa protein levels. Data are mean ± SE with number (n) of
tumors indicated. Asterisks indicate p < 0.01.
(C) Anchorage-independent growth assays of the indicated HCEC cells were performed in presence of the indicated concentrations of A769662. Number of
colonies >100 mm were counted (n = 3). Data are mean ± SD. Asterisks indicate p < 0.05.
(D) Colony formation assays were performed in HeLa cells treated with the indicated siRNAs. Data are mean ± SD, n = 3. Asterisks indicate p < 0.05.
See also Figures S4 and S5.Colony Formation and Anchorage-Independent Growth Soft Agar
Assays
For colony formation assays on plastic, cells were transfected for 72 hr
with siRNAs and then re-plated at single-cell density. After 3 weeks,
cells were fixed and stained with crystal violet (0.05% [w/v]) and counted.
For anchorage-independent growth soft agar growth assays, cells
were suspended in 0.375% Noble agar (Difco) supplemented with(B) U2OS cells stably expressing GFP-LC3 were treated with the indicated siRNAs
are mean and quartiles.
(C) U2OS cells stably expressing GFP-LC3were treatedwith the indicated siRNAs
cells.
(D and E) Seventy-two hours after transfection, cells were stained for endogeno
Boxplots are mean and quartiles of n > 50 cells.
(F) U2OS cells were transfected with the indicated siRNA for 72 hr before treatmen
and quartiles of n > 50 cells.
(G) U2OS GFP-LC3 cells were transfected with the indicated siRNA for 72 hr. Me
(n = 3).
(H) Cells stably expressing GFP-LC3 were treated with siRNAs for 72 hr before i
(I) Knockdown of MAGE-A3/6 or TRIM28 increases autophagic flux. GFP-LC3 ce
bafilomycin A for 4 hr before cell lysates were immunoblotted (n = 3).
(J and K) Knockdown of MAGE-A3/6 or TRIM28 increases p62 consumption. He
were collected (J) or cells were treated with DMSO or bafilomycin A for 4 hr befo
immunoblotting (nR 2).
(L) MAGE-A3/6-negative HBEC cells were stably transfected with Myc-MAGE-A
Asterisks indicate p < 0.05. See also Figure S3.regular growth medium and overlaid on 0.5% Noble agar. Cells were al-
lowed to grow for 2–4 weeks before colonies R100 mm in size were
counted.
Immunofluorescence and Microscopy
Immunofluorescence was performed essentially as described previously (Hao
et al., 2013) and in Extended Experimental Procedures.for 72 hr before imaging and quantitation of GFP-LC3 puncta (n = 3). Boxplots
for 72 hr before imaging (n = 3). Boxplots representmean and quartiles of n > 50
us LC3 (D). Scale bars, 20 mm. Boxplots of number of LC3 puncta per cell (E).
t for 4 hr with 10 mMcompound C or vehicle (DMSO). Boxplots represent mean
dian GFP fluorescent intensity ±SD as determined by flow cytometry is shown
mmunoblotting (n > 3).
lls were transfected with the indicated siRNA for 72 hr. Cells were treated with
La or U2OS cells were treated with the indicated siRNA for 72 hr. Cell lysates
re cell lysates were collected (K), and the indicated proteins were detected by
3, and cell lysates were immunoblotted (n = 2).
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In Vitro Ubiquitination Screen
ProtoArray containing >9,000 GST-tagged recombinant proteins purified from
SF9 insect cells was purchased from Invitrogen. In vitro ubiquitination on the
slide was performed according to manufacture instructions with minor modi-
fications described in Extended Experimental Procedures.
Glucose Consumption and Lactate Measurements
Twenty-four hours after plating, cells were transfected with siRNA. Seventy-
two hours after siRNA transfections, cells were changed into fresh media for
6 hr. Media was collected and analyzed using Nova Analyzer to quantitate
amount of glucose and lactate in the media.
Recombinant Protein Purification and In Vitro Binding Assays
Recombinant proteins were produced using standard procedures described in
Extended Experimental Procedures. In vitro binding assayswere performed as
described previously (Doyle et al., 2010; Hao et al., 2013) and specified in the
Experimental Procedures.
Assessment of mRNA/Protein Expression Levels in Human Tumors
and Statistical Analysis
mRNA levels, survival data, and mutational status were determined using the
cancer genome atlas. Tumor protein expression levels were determined previ-
ously by reverse-phase protein arrays performed on tumors with matching
RNA sequencing data (Cancer Genome Atlas Research Network, 2014).
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